Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Protein fragment found to help improve chemotherapy

21.05.2003


USC researchers find ways to improve effectiveness against tumors



Researchers from the Keck School of Medicine of the University of Southern California have isolated a protein fragment derived from the cancer immunotherapy drug interleukin 2 (IL-2) that seems to enhance the uptake of chemotherapeutic agents into tumors.

In fact, says Alan Epstein, M.D., Ph.D., professor of pathology at the Keck School of Medicine, when this patented protein fragment is attached to a tumor-targeting antibody, it can prompt tumors to soak up more than 300 percent the normal amount of chemotherapy drugs. It does this, Epstein says, by making the tumor’s blood vessel walls more "open" or permeable to the drugs. (Blood vessel walls are made of epithelial cells that are usually tightly joined together; when the junctions between those cells loosen up, it becomes easier for molecules to enter or leave the bloodstream.)


This work was described in a paper being published in the May 21, 2003 issue of the Journal of the National Cancer Institute.

The interleukins are part of a class of proteins called cytokines, which play a role in the human immune response. It’s been hoped that interleukin 2 (IL-2) and its brethren might play a central role in cancer immunotherapy-battling cancer by revving up the immune system. Unfortunately, IL-2 can only be tolerated in small doses by the body. Taken at levels that would take advantage of its therapeutic value, it causes wide-spread edema and other problems due to blood vessel leakiness.

While seeking the cause of this leakiness, Epstein and his Keck School of Medicine colleagues isolated a stretch of 37 amino acids on the IL-2 protein; this sequence, he says, "is responsible for 100 percent of the vasopermeability." Dubbed PEP, for permeability-enhancing peptide, the molecule is now being commercially developed by Peregrine Pharmaceuticals of Tustin, Calif.

Having determined that PEP is indeed a permeability enhancer, Epstein and his colleagues took their exploration a step further: They transplanted mice with human tumor cells and pretreated them with monoclonal antibodies coupled with PEP.

When these mice and control mice were later injected with a radiolabeled tracer antibody or drug, there was a three to four fold increase in the amount of the antibody taken up by the tumors of the pretreated mice than those of the control mice.

"We’ve showed that you can use PEP to induce selective and reversible blood vessel permeability at the tumor site to get better drug uptake," says Epstein. "This may turn out to be a hugely important tool in cancer therapy."

The next step, he says, "is to try to get this product ready to test in human patients."


###
This work was supported by grants from the National Cancer Institute, Peregrine Pharmaceuticals, Inc. and Cancer Therapeutics Laboratories.

Alan L. Epstein, Myra Mizokami, Jiali Li, Peisheng Hu, Leslie A. Khawli, "Identification of a Protein Fragment of Interleukin 2 Responsible for Vasopermeability." Journal of the National Cancer Institute, Vol. 95, No. 10, May 21, 2003, pp. 741-749.

Jon Weiner | EurekAlert!
Further information:
http://www.usc.edu/

More articles from Health and Medicine:

nachricht Oxygen can wake up dormant bacteria for antibiotic attacks
08.12.2016 | Penn State

nachricht NTU scientists build new ultrasound device using 3-D printing technology
07.12.2016 | Nanyang Technological University

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

Closing the carbon loop

08.12.2016 | Life Sciences

Applicability of dynamic facilitation theory to binary hard disk systems

08.12.2016 | Physics and Astronomy

Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D

08.12.2016 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>